Thu, Feb 20, 2020
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Amita Schultes joins Perella Weinberg Partners Agility

Thursday, October 26, 2017
Opalesque Industry Update - Agility, the Outsourced Chief Investment Officer business of Perella Weinberg Partners (PWP), today announced Amita Schultes, PhD has joined the Firm as a Managing Director. Dr. Schultes, who will be based in New York, will be a member of Agility's Investment Team, working with endowments and foundations and other institutional clients across the United States.

Dr. Schultes joins Perella Weinberg Partners from Colonial Consulting where she was a Partner, Managing Director and Senior Consultant. In this role she served as the sole investment consultant to numerous non-profit institutional investors and pension plans, advising clients on the management of their investment portfolios. Previously, she was a Senior Consultant at Ibbotson Associates where she developed asset allocation programs for asset management companies, insurance companies and broker dealers. Dr. Schultes began her career at Salomon Smith Barney.

Chris Bittman, Agility CEO and CIO and Partner at PWP, stated, "There has been tremendous growth in investment outsourcing as endowments and foundations increasingly look to build more diversified portfolios amid volatile and complex markets. We are excited to have Amita join the Agility team. Her experience and skills will be invaluable to our clients as we develop customized investment solutions to meet their unique needs."

Amita Schultes stated, "Agility has positioned itself as a leading OCIO provider with a disciplined investment process and a true partnership with their clients. I look forward to working with my colleagues and leveraging my experience to contribute to the success of our team."

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. PE/VC: Venture debt: Is it a loan? Is it equity? Is it an pportunity?, PE, VC investments in India hit all-time high in 2019[more]

    Venture debt: Is it a loan? Is it equity? Is it an pportunity? From Forbes: Venture Capital is usually the default option for fast-growth startups looking for a cash injection, thanks to our willingness to take risks in return for equity, and with no need to pay anything back - at least

  2. Other Voices: Evolution of shrinking hedge fund fees - what do investors and managers need to know?[more]

    By Don Steinbrugge, Founder and CEO, Agecroft Partners (DonSteinbrugge@agecroftpartners.com): Hedge funds fees remain under extreme pressure across the industry. This strong trend is driven by declining return expectations from investors, inc

  3. COVID-19: Investors track ships, chase rumours to get edge on COVID-19 risks, Coronavirus risk puts the bull run on pause, China was wise to let markets stumble[more]

    Investors track ships, chase rumours to get edge on COVID-19 risks From Reuters: As investors crunch numbers to determine how the coronavirus will hit China's economy, hedge fund manager Nathaniel Polachek has tied much of his outlook to the fate of a ship anchored near Weihai, China.

  4. Bruce Berkowitz is back!, Coatue's new quant fund lost money in the fourth quarter[more]

    Bruce Berkowitz is back! From Institutional Investor: Famed value investor Bruce Berkowitz has hit hard times over the past decade, with big bets on losers like Eddie Lampert's Sears Holdings. In fact, over the past 10 years, his Fairholme Fund's annualized return is only 4.89 percent -

  5. Opalesque Exclusive: Optima A.M. bets on healthcare and biotech innovations with long/short strategy[more]

    B. G., Opalesque Geneva: Optima Asset Management has just launched the Optima Healthcare and Biotechnology strategy, which will be managed by five portfolio managers